Anktiva FDA Approval: Powerful New Option for Bladder Cancer
Anktiva FDA approval now covers BCG-unresponsive bladder cancer with papillary-only tumours as well as CIS. See the data, dosing, safety warnings and caveats.
Anktiva FDA approval now covers BCG-unresponsive bladder cancer with papillary-only tumours as well as CIS. See the data, dosing, safety warnings and caveats.